XTRA:AFXMedical Equipment
Why Carl Zeiss Meditec (XTRA:AFX) Is Down 18.2% After Cutting 2025/26 Revenue and Margin Guidance - And What's Next
Carl Zeiss Meditec AG announced in January 2026 that its prior fiscal 2025/26 guidance of around €2.3 billion in revenue and a 12.5% EBITA margin will likely not be achieved, citing uncertainties tied to geopolitics, trade barriers, regulation, and key tender processes.
An important nuance is that management linked the guidance review not only to regulatory and tender risks in China but also to the timing of the winter seasonal peak for refractive treatment packs, highlighting how...